作者: Craig J. Galbán , Stefanie Galbán , Marcian E. Van Dort , Gary D. Luker , Mahaveer S. Bhojani
DOI: 10.1016/B978-0-12-385071-3.00009-5
关键词: Cancer 、 Emission computed tomography 、 Nuclear medicine 、 Fluorescence-lifetime imaging microscopy 、 Biomarker (cell) 、 Preclinical imaging 、 Radiology 、 Positron emission tomography 、 Magnetic resonance imaging 、 Molecular imaging 、 Medicine
摘要: Today molecular imaging technologies play a central role in clinical oncology. The use of techniques early cancer detection, treatment response, and new therapy development is steadily growing has already significantly impacted on management cancer. In this chapter, we overview three different used for the understanding disease biomarkers, drug development, or monitoring therapeutic outcome. They are (1) optical (bioluminescence fluorescence imaging), (2) magnetic resonance (MRI), (3) nuclear (e.g., single-photon emission computed tomography (SPECT) positron (PET)). We review reporters biological processes apoptosis protein kinase activity) high-throughput screening therapies, diffusion MRI as biomarker response PET SPECT radioligands